Hepatitis B vaccination and undifferentiated connective tissue disease: another brick in the wall of the autoimmune/inflammatory syndrome induced by adjuvants (Asia).
C. Perricone,Y. Shoenfeld
DOI: https://doi.org/10.1097/RHU.0b013e31829d56f1
2013-08-01
Journal of Clinical Rheumatology
Abstract:Nowadays, dealing with the diagnosis of undifferentiated connective tissue disease (UCTD) can be a tricky game. Indeed, it has been underlined from several points of evidence that classifying this pauci-symptomatic condition can be a matter of debate. Undifferentiated connective tissue disease shares most of the epidemiological characteristics as well as the immunopathogenic pathways of other well-defined autoimmune conditions. However, in this limbo, patients with UCTD risk are being thrown all together in a cauldron where less attention is paid in determining the etiology and the precise mechanisms leading to such an often difficult to validate condition. This, in turn, may delay the discovery of proper and specific treatments. Bruzzese et al., in this issue of the Journal of Clinical Rheumatology, described the onset of UCTD following hepatitis B virus (HBV) vaccination. The authors emphasized that the patient, a 43-year-old woman, started suffering from a constellation of unspecific symptoms including paresthesias, arthralgias, alopecia, arthritis, and asthenia, soon after the second dose of HBV vaccine. Moreover, the rise of an autoimmune response was documented by the comparison of antinuclear antibodies. It is clear that the patient could not have been classified in any of the known well-defined autoimmune conditions. On the other hand, the patient fulfilled the proposed criteria for the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Since the birth of medicine, physicians have been classifying patients by covering under the same umbrella those sharing similar clinical features. The term ‘‘undifferentiated’’ has been used to include all those conditions in which a well-defined diagnosis could not be reached. However, in recent years, science has demonstrated that, to create effective treatments, even more important than the clinical picture is the underlying etiopathogenic mechanism. This is especially true in the field of autoimmunity. Indeed, when dealing with cancer, the therapy aims at destroying the specific demented cell. When dealing with infectious diseases, physicians pay less care if the patient has fever or splenomegaly, whereas the objective is killing the pathogenic microorganism. However, in the field of autoimmunity, the causes of each disease are multiple, encompassing the ‘‘mosaic of autoimmunity.’’ Most of the pathogenic mechanism and etiological grounds are unclear, undefined, or at least hard to find. This is the reason why medical science is addressing with the autoimmune process rather than the eliciting trigger. The discovery or, rather, the depiction of ASIA has changed for the first time this view toward the gathering of patients sharing a related picture but, more relevantly, linked by the same pathogenic mechanism: the adjuvant. Autoimmune/inflammatory syndrome induced by adjuvants and UCTD share a common fate: both are ‘‘undifferentiated,’’ meaning that there is no specific clinical feature characterizing each entity, and both can shift toward a definite autoimmune disease. Indeed, the overlap between the 2 conditions is evident as shown in the Table.